145 related articles for article (PubMed ID: 11290565)
1. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus.
Shin YK; Choi EY; Kim SH; Chung J; Chung DH; Park WS; Jung KC; Kim HS; Park S; Kim HJ; Park MH; Min CK; Kim CC; Park SH
Am J Pathol; 2001 Apr; 158(4):1473-80. PubMed ID: 11290565
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow.
Terstappen LW; Huang S; Picker LJ
Blood; 1992 Feb; 79(3):666-77. PubMed ID: 1370641
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia.
Kim TJ; Park SH
J Korean Med Sci; 1998 Oct; 13(5):455-8. PubMed ID: 9811172
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood.
Dworzak MN; Fritsch G; Buchinger P; Fleischer C; Printz D; Zellner A; Schöllhammer A; Steiner G; Ambros PF; Gadner H
Blood; 1994 Jan; 83(2):415-25. PubMed ID: 7506950
[TBL] [Abstract][Full Text] [Related]
5. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.
Kim MS; Park CJ; Cho YU; Jang S; Seo EJ; Park CS; Huh J; Im HJ; Seo JJ; Yoon DH; Suh C
Ann Lab Med; 2020 Jan; 40(1):1-6. PubMed ID: 31432632
[TBL] [Abstract][Full Text] [Related]
6. JL1, a novel differentiation antigen of human cortical thymocyte.
Park SH; Bae YM; Kwon HJ; Kim TJ; Kim J; Lee SJ; Lee SK
J Exp Med; 1993 Oct; 178(4):1447-51. PubMed ID: 8376947
[TBL] [Abstract][Full Text] [Related]
7. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias.
Park WS; Bae YM; Chung DH; Kim TJ; Choi EY; Chung JK; Lee MC; Park SY; Park MH; Park SH
Leukemia; 1998 Oct; 12(10):1583-90. PubMed ID: 9766503
[TBL] [Abstract][Full Text] [Related]
8. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
Shin YK; Choi YL; Choi EY; Kim MK; Kook MC; Chung J; Choi YK; Kim HS; Song HG; Park SH
Cancer Immunol Immunother; 2003 Aug; 52(8):506-12. PubMed ID: 12768327
[TBL] [Abstract][Full Text] [Related]
9. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
[TBL] [Abstract][Full Text] [Related]
10. Expression of JL1 is an effective adjunctive marker of leukemia cutis.
Park YS; Park SH; Park SJ; Kim Y; Jang KT; Ko YH; Lee MW; Huh JR; Park CS
Arch Pathol Lab Med; 2010 Jan; 134(1):95-102. PubMed ID: 20073611
[TBL] [Abstract][Full Text] [Related]
11. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.
Dworzak MN; Fritsch G; Fleischer C; Printz D; Fröschl G; Buchinger P; Mann G; Gadner H
Leukemia; 1997 Aug; 11(8):1266-73. PubMed ID: 9264380
[TBL] [Abstract][Full Text] [Related]
12. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood.
Fritsch G; Stimpfl M; Kurz M; Printz D; Buchinger P; Fischmeister G; Hoecker P; Gadner H
Bone Marrow Transplant; 1996 Feb; 17(2):169-78. PubMed ID: 8640162
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells.
Hurwitz CA; Gore SD; Stone KD; Civin CI
Leukemia; 1992 Apr; 6(4):233-9. PubMed ID: 1375301
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
15. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
16. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells.
Saeland S; Duvert V; Caux C; Pandrau D; Favre C; Vallé A; Durand I; Charbord P; de Vries J; Banchereau J
Exp Hematol; 1992 Jan; 20(1):24-33. PubMed ID: 1374342
[TBL] [Abstract][Full Text] [Related]
17. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
[TBL] [Abstract][Full Text] [Related]
18. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
19. Multiparameter flow cytometric analysis of human fetal bone marrow B cells.
LeBien TW; Wörmann B; Villablanca JG; Law CL; Steinberg LM; Shah VO; Loken MR
Leukemia; 1990 May; 4(5):354-8. PubMed ID: 1697009
[TBL] [Abstract][Full Text] [Related]
20. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
Kahng J; Shin SY; Han K
Korean J Lab Med; 2007 Dec; 27(6):406-13. PubMed ID: 18160830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
